Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation. (October 2022) - Fujino, T.; Nguyen, L.; Yoda, S.; Yu, M.; Mizuta, H.; Bigot, L.; Nobre, C.; Tangpeerachaikul, A.; Pelish, H.E.; Friboulet, L.; Lee, J.; Cho, B.; et al.